Published Paper Details:

Idiopathic pulmonary fibrosis (IPF) is a common and deadly fibrotic lung disease with a median survival time of 2 to 3 years. It is characterized by chronic, progressive fibrosis that worsens over time and is linked to high mortality, progressive respiratory failure, and loss of lung function. Diagnosing IPF requires clinicians to integrate clinical, laboratory, radiologic, and pathologic data. Epidemiologically, IPF primarily affects older adults, with prevalence increasing with age, especially in those over 60. Gender and race differences exist, and risk factors include smoking, environmental exposures, and genetics. IPF is often associated with comorbidities, and its prognosis varies, with a median survival of 3 to 5 years. Early detection of pulmonary fibrosis is crucial for better outcomes, relying on clinical history, physical examination, pulmonary function tests, imaging, biomarkers, and, in some cases, genetic testing. Early intervention may slow disease progression. Currently, no established therapy exists for IPF, but new approaches aim to minimize acute lung injury consequences. Medications such as azathioprine and cyclophosphamide, and interventions like lung transplantation, have been explored with varying success. IPF poses a significant threat to society, necessitating ongoing research efforts for effective therapeutic targets. Understanding the molecular mechanisms underlying IPF development is crucial for future investigations and the development of successful treatments.